Menu Search
Equities

CorMedix Inc

CRMD:NMQ

CorMedix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.96
  • Today's Change-0.37 / -3.58%
  • Shares traded879.68k
  • 1 Year change+172.13%
  • Beta1.5666
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year CorMedix Inc's revenues fell -100.00% from 65.41k to 0.00. has fallen 56.02% from a loss of 29.70m to a larger loss of 46.34m.
Gross margin83.57%
Net profit margin-376.35%
Operating margin-415.59%
Return on assets-54.61%
Return on equity-65.04%
Return on investment-64.60%
More ▼

Cash flow in USDView more

In 2023, CorMedix Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 55.92m or -- of revenues. In addition the company used 38.41m for operations while cash used for investing totalled 17.06m.
Cash flow per share-0.7943
Price/Cash flow per share--
Book value per share1.01
Tangible book value per share0.9815
More ▼

Balance sheet in USDView more

CorMedix Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio3.96
Quick ratio3.60
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.